105 Matching Annotations
  1. Last 7 days
    1. Miguel Hernán. (2021, February 15). To all who claim that there’s no evidence that #SARSCoV2 is transmitted in bars: If the risk of transmitting #SARSCoV2 is provenly greater in crowded indoor places, why should bars be magically protected? Burden of the proof is on bar’s owners, not on scientists @BillHanage [Tweet]. @_MiguelHernan. https://twitter.com/_MiguelHernan/status/1361463022187864066

  2. Jun 2021
  3. May 2021
    1. .

      Since publication, the FDA has rescinded its authorisation of bamlanivimab (LY-CoV555), due to its lack of efficacy against circulating variants of concern, particularly B.1.351 (South African), as a result of E484K substitution A,B. Eli Lilly are now pursuing the use of their combination therapy of bamlanivimab with etesevimab (LY-CoV016).

      The antibody cocktail REGN-CoV2 showed sustained efficacy against tested variant strains and thus remains a viable treatment option. However, a mutational library scan by Starr et al. revealed that a single amino acid change (E406W) is all that is required for a future variant to escape this therapy C.

      Circulating variants highlight the limited efficacy of monoclonal antibodies to an evolving virus, particularly in those which are restricted to the RBD. A diverse panel of monoclonal antibodies, which bind subdominant epitopes may be a more sustainable approach.

      A – Wang, P et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 2021. Nature. https://doi.org/10.1038/s41586-021-03398-2

      B – Starr, T.N.et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal LY-CoV555 and its cocktail with LY-CoV016. 2021. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2021.100255

      C – Starr, T.N.et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. 2021. Science. https://doi.org/10.1126/science.abf9302

  4. Apr 2021
    1. Acquiring viral drift sufficient to produce new influenza strains capable of escaping population immunity is believed to take years of global circulation, not weeks of local circulation.

      Experiencing enough viral drift to produce an influenza variant capable of escaping population immunity is believed to take years of global circulation (not weeks of local circulation).

  5. Mar 2021
    1. Amy Maxmen, PhD. (2020, August 26). 🙄The CDC’s only substantial communication with the public in the pandemic is through its MMW Reports. But the irrelevant & erroneous 1st line of this latest report suggests political meddling to me. (The WHO doesn’t declare pandemics. They declare PHEICs, which they did Jan 30) https://t.co/Y1NlHbQIYQ [Tweet]. @amymaxmen. https://twitter.com/amymaxmen/status/1298660729080356864

    1. Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., Graham, B. S., Mascola, J. R., Chang, J. Y., Yin, M. T., Sobieszczyk, M., Kyratsous, C. A., Shapiro, L., Sheng, Z., Huang, Y., & Ho, D. D. (2021). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature, 1–9. https://doi.org/10.1038/s41586-021-03398-2

    1. ReconfigBehSci. (2020, November 3). As debate on ‘saving the economy versus saving lives’ marches on, it’s worth noting that this type of contrast actually has a name in fallacy research: Https://t.co/N8U4ABWTuh it’s also worth noting that there is now a substantial number of research articles on the topic. 1/n [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1323603017179013130

  6. Feb 2021
    1. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Lambson, B. E., Vermeulen, M., Berg, K. van den, Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., Gottberg, A. von, Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv, 2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166

  7. Jan 2021
    1. This variant presents 14 non-synonymous mutations, 6 synonymous mutations and 3 deletions. The multiple mutations present in the viral RNA encoding for the spike protein (S) are of most concern, such as the deletion Δ69-70, deletion Δ144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
  8. Dec 2020
  9. Oct 2020
  10. Sep 2020
  11. Aug 2020
    1. Amanat, F., White, K. M., Miorin, L., Strohmeier, S., McMahon, M., Meade, P., Liu, W.-C., Albrecht, R. A., Simon, V., Martinez‐Sobrido, L., Moran, T., García‐Sastre, A., & Krammer, F. (2020). An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Current Protocols in Microbiology, 58(1), e108. https://doi.org/10.1002/cpmc.108

  12. Jul 2020
  13. Jun 2020
  14. May 2020
    1. Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., Marrama, D., de Silva, A. M., Frazier, A., Carlin, A., Greenbaum, J. A., Peters, B., Krammer, F., Smith, D. M., Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, S0092867420306103. https://doi.org/10.1016/j.cell.2020.05.015

  15. Apr 2020
  16. Mar 2020